17551-52-9

Usage

Uses

Used in Pharmaceutical Industry:
4(1H)-Pyrimidinone, 6-chloro-2-methyl(9CI) is used as an intermediate for the synthesis of various therapeutic agents. Its primary application is in the preparation of highly potent hepatitis C virus (HCV) entry inhibitors, which are crucial in the development of treatments for hepatitis C.
Additionally, 4(1H)-Pyrimidinone, 6-chloro-2-methyl- (9CI) is utilized in the synthesis of pyrimidineacetic acids and (Pyrimidinyloxy)acetic acids, which serve as aldose reductase inhibitors. Aldose reductase inhibitors are important in the management of diabetic complications, such as neuropathy and retinopathy, by reducing the harmful effects of high sugar levels on the body.

InChI:InChI=1/C5H5ClN2O/c1-3-7-4(6)2-5(9)8-3/h2H,1H3,(H,7,8,9)

Upstream product

• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 40497-30-1 2-methyl-1H-pyrimidine-4,6-dione 

Downstream Products

• 106660-26-8 6-(3,4-Dimethyl-phenylamino)-2-methyl-3H-pyrimidin-4-one 
• 106660-25-7 2-Methyl-6-m-tolylamino-3H-pyrimidin-4-one 
• 105806-11-9 2-methyl-4-hydroxy-5-bromo-6-chloropyrimidine 
• 13162-43-1 4,6-dichloro-2-methyl-5-nitropyrimidine 
• 82779-50-8 4,6-dichloro-2-methyl-5-nitropyrimidine 
• 63586-33-4 6-chloro-2-methyl-5-nitro-pyrimidin-4-ylamine 
• 111079-21-1 4,6-dichloro-5-iodo-2-methylpyrimidine 
• 1419747-01-5 C₁₆H₁₇N₃O₂ 
• 1293282-91-3 6-[5-{[2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-methylpyrimidin-4(3H)-one 
• 700810-97-5 6-chloro-2-methyl-N-phenylpyrimidin-4-amine 

Relevant academic research and scientific papers

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead

Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma, and non-small-cell lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors, and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wild-type RET (wtRET) and its mutants (e.g., V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor, N-(2-fluoro-5-trifluoromethylphenyl)-N′-{4′-[(2′′-benzamido)pyridin-4′′-ylamino]phenyl}urea (69), endowed with a 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound. Profiling against a panel of kinases indicated 69 as a multi cKIT/wtRET/V804MRET inhibitor.

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.

Isoxazolines as Therapeutic Agents

The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I) in free base form or in acid addition salt form, in which R1, R2, R3, R4 and A are as defined in the specification, to their preparation, to their use as medicaments for the treatment of certain nervous system disorders and to medicaments comprising them.

5-substituted-6-aminopyrimidines, composition and uses as cardiotonic agents for increasing cardiac contractility

Herein is disclosed amino-pyrimidine derivatives, therapeutically acceptable acid addition salts thereof, processes for their preparation, methods of using the derivatives and pharmaceutical compositions. The derivatives are useful for increasing cardiac contractility in a mammal.